Severe exacerbations predict excess lung function decline in asthma.
about
An official American Thoracic Society statement: work-exacerbated asthmaAsthma: clinical expression and molecular mechanismsMouse models of acute exacerbations of allergic asthmaThe Danish National Database for Asthma: establishing clinical quality indicatorsAsthma outcomes: exacerbationsIdentification and management of adults with asthma prone to exacerbations: can we do better?Immunohistology and remodeling in fatal pediatric and adolescent asthma.Asthma and chronic obstructive pulmonary diseaseAzithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation.The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.Chinese expert consensus on bronchial asthma control.Clinical characteristics of asthma combined with COPD featureDecreased activation of inflammatory networks during acute asthma exacerbations is associated with chronic airflow obstruction.Smoking, longer disease duration and absence of rhinosinusitis are related to fixed airway obstruction in Koreans with severe asthma: findings from the COREA studyCharacterization of lung function impairment in adults with bronchiectasis.Current recommendations for the treatment of mild asthma.The irreversible component of persistent asthma.Update on optimal use of omalizumab in management of asthma.Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children.Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation.Obstructive sleep apnoea accelerates FEV1 decline in asthmatic patients.Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working GroupPreseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.Immunologic and inflammatory mechanisms that drive asthma progression to remodelingThe Clinical and Health Economic Value of Clinical Laboratory DiagnosticsLost to follow-up in asthmatics does not mean treatment failure: causes and clinical outcomes of non-adherence to outpatient treatment in adult asthma.Hypoxia potentiates allergen induction of HIF-1α, chemokines, airway inflammation, TGF-β1, and airway remodeling in a mouse modelAcute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype.Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.Protocol for a systematic review to identify and weight the indicators of risk of asthma exacerbations in children aged 5-12 years.Bronchial thermoplasty: a novel therapy for severe asthma.Airway gene expression of IL-1 pathway mediators predicts exacerbation risk in obstructive airway disease.Epidemiology of the origins of airflow limitation in asthma.Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations.What is severe asthma?Exacerbations of severe asthma.Efficacy of anticholinergic drugs in asthma.Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.Assessing the risk of attack in the management of asthma: a review and proposal for revision of the current control-centred paradigm.Fungus-associated asthma: overcoming challenges in diagnosis and treatment.
P2860
Q23919332-C758614B-C439-4D68-939A-1F1593BC05DCQ24597331-5A8CEA7A-3CF6-42A1-AC8B-107F8317CD77Q26765990-73C73D55-3598-4B54-8CE0-B3030143A04EQ28074257-4435880A-888A-4034-855A-D3AF9DB52F9AQ30421935-29962A8B-F84E-489E-9B81-7A99489CA068Q33396567-1C511906-C715-42D6-B619-7D62D1CAE39BQ33696855-343764D1-6184-4D1A-9869-27E8B3163501Q33706788-F913C076-E817-4B39-A1A0-E3C8A87C2084Q33761836-7EDDD760-6897-4BA1-92FD-796B8825A9FEQ33786076-81790D3D-A762-4C91-BE6C-4B609CE218A7Q33814652-C689A6E7-691D-43C6-ACF5-089026866364Q33822616-2F5EBC82-3EF2-46F4-AC8A-830E5957C6A8Q33937638-FD1E677D-F515-499B-AA5D-860480D12D49Q34499210-EAEFCD36-64B5-4FEF-B168-1B6E4B4D2B4BQ34535955-47D7896F-E117-495E-9C02-4149FBE177B7Q34620134-BE4AF9F1-CB66-4E82-9ADF-513D89A3FBDEQ34813083-DE2ADD53-462C-4196-8053-DD7883264D0AQ35117827-6BD9CAAF-603A-450D-B817-5E561E2EA970Q35968014-AF165A11-899C-47CB-A0EB-B3DF3165E735Q36140977-E9358C1A-8468-465F-B504-14A58998C4B8Q36317534-CBF52B38-8E77-41DF-9963-8BC0F1188890Q36364500-5093B353-1A22-4756-9F82-590BAD31FE5FQ36373455-07DC37F0-5209-4CDA-929F-BB9E4589E9DDQ37105324-B9C6E7BD-3B1C-4CBA-98EF-5124923F79A2Q37155167-B29F5905-E859-48D5-8421-E6B27381C0E7Q37261427-68F5181C-7A46-4BAB-900F-AED8615DB59DQ37265367-E006CE03-8CCB-43E3-89A0-73910716AA44Q37315359-41E99CD7-9729-4FE6-91FB-533ECB684D2EQ37362634-DE003ACD-E9B6-4C57-873C-B367A224D941Q37560263-A9FC4841-A8BF-4D30-AF9B-33082B1EDAC6Q37592328-501C4462-B093-4B3F-A8B9-59B085ABBAF8Q37641498-C0A7C178-D3EB-43B2-B056-0908BD2B1AD4Q37653495-5018EA5D-1323-4452-9169-5B95DE785DF0Q37736830-5D0A3194-1218-4B2E-AF09-86BC0BF9E030Q38003658-79CACDB3-981E-4C8C-A605-BD1B3CDBF340Q38003660-516D4C89-6B38-43CE-A607-F717752293EBQ38025727-9A7B4476-7999-4B51-9C3E-76753DECA730Q38066413-0B1216C1-BCA0-405D-8DB3-22B1372E46E9Q38118606-49836E6F-4053-4DD0-B601-E3179DF6536DQ38192062-B9EF5DA1-85CC-4B03-8D09-4F07D9EA68F6
P2860
Severe exacerbations predict excess lung function decline in asthma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Severe exacerbations predict excess lung function decline in asthma.
@en
Severe exacerbations predict excess lung function decline in asthma.
@nl
type
label
Severe exacerbations predict excess lung function decline in asthma.
@en
Severe exacerbations predict excess lung function decline in asthma.
@nl
prefLabel
Severe exacerbations predict excess lung function decline in asthma.
@en
Severe exacerbations predict excess lung function decline in asthma.
@nl
P2093
P1476
Severe exacerbations predict excess lung function decline in asthma.
@en
P2093
P304
P356
10.1183/09031936.00165106
P577
2007-05-30T00:00:00Z